Lyra Therapeutics Inc (LYRA)

  • Get an in-depth profile of Lyra Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
3.800 -0.120 (-3.06%)
Closed USD Disclaimer

Lyra Therapeutics Inc Company Profile

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
59
Equity Type
ORD
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company has two investigational product candidates, LYR-210 and LYR-220, in late-stage development for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210 and LYR-220 are bioresorbable nasal implants designed to be administered in a brief, in-office procedure and are intended to deliver six months of continuous mometasone furoate drug therapy to the sinonasal passages. LYR-210 is designed for surgically naive patients and is being evaluated in the ENLIGHTEN Phase III clinical program, while LYR-220, an enlarged implant, is being evaluated in the BEACON Phase II clinical trial in patients who have recurrent symptoms despite having had prior ethmoid sinus surgery.
Contact Information
Address
Watertown,02472 United States
Phone
617 393 4600
Fax
-
Web
https://lyratherapeutics.com
Top Executives
Name
Age
Since
Title
W. Bradford Smith 66 2019 Independent Director
C. Ann Merrifield 71 2019 Independent Director
Gary M. Ansel 0 0000 Member of Medical Advisory Board
Martin Schillinger 0 0000 Member of Medical Advisory Board
Elazer R. Edelman 65 0000 Member of Scientific Advisory Board
I. Baumgartner 0 0000 Member of Medical Advisory Board
Robert S. Langer 73 2006 Member of Scientific Advisory Board
George M. Whitesides 83 2006 Member of Scientific Advisory Board
Renu Virmani 0 0000 Member of Scientific Advisory Board
Michael D. Dake 0 0000 Member of Medical Advisory Board
Mark Saltzman 0 0000 Member of Scientific Advisory Board
Konstantin Poukalov 38 2020 Independent Director
Michael Seth Altman 40 2018 Independent Director
William A. Gray 0 0000 Member of Medical Advisory Board
Robert S. Schwartz 0 0000 Member of Scientific Advisory Board
James Morley Anderson 81 0000 Member of Scientific Advisory Board
Mahmood K. Razavi 0 0000 Member of Medical Advisory Board
Stephen L. Hilbert 0 0000 Member of Scientific Advisory Board
Nancy L. Snyderman 69 2020 Independent Director
James R. Tobin 77 2022 Lead Independent Director
Edward Thomas Anderson 70 2019 Independent Director
Maria Palasis 58 2015 CEO, President & Director
Harlan W. Waksal 70 2022 Executive Chairman

Customize

Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.